182 related articles for article (PubMed ID: 35858914)
1. Granulocyte colony stimulating factor use and adherence to clinical practice guidelines among women with breast cancer living in Puerto Rico: a population-based study.
Jiménez Nieves Y; Ortiz-Ortiz KJ; Ríos Motta RE; Castañeda-Avila MA; Tortolero-Luna G
BMC Health Serv Res; 2022 Jul; 22(1):935. PubMed ID: 35858914
[TBL] [Abstract][Full Text] [Related]
2. Trends in Use of Granulocyte Colony-Stimulating Factor Following Introduction of Biosimilars Among Adults With Cancer and Commercial or Medicare Insurance From 2014 to 2019.
Wang CY; Heldermon CD; Vouri SM; Park H; Wheeler SE; Ramnaraign BH; Dang NH; Brown JD
JAMA Netw Open; 2021 Nov; 4(11):e2133474. PubMed ID: 34812849
[TBL] [Abstract][Full Text] [Related]
3. Patterns of primary prophylactic granulocyte colony-stimulating factor use in older Medicare patients with cancer receiving myelosuppressive chemotherapy.
Schenfeld J; Gong T; Henry D; Kelsh M; Gawade P; Peng Y; Bradbury BD; Li S
Support Care Cancer; 2022 Jul; 30(7):6327-6338. PubMed ID: 35482126
[TBL] [Abstract][Full Text] [Related]
4. The use of granulocyte colony stimulating factor (G-CSF) and management of chemotherapy delivery during adjuvant treatment for early-stage breast cancer--further observations from the IMPACT solid study.
Mäenpää J; Varthalitis I; Erdkamp F; Trojan A; Krzemieniecki K; Lindman H; Bendall K; Vogl FD; Verma S
Breast; 2016 Feb; 25():27-33. PubMed ID: 26801413
[TBL] [Abstract][Full Text] [Related]
5. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
Aapro MS; Bohlius J; Cameron DA; Dal Lago L; Donnelly JP; Kearney N; Lyman GH; Pettengell R; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
Eur J Cancer; 2011 Jan; 47(1):8-32. PubMed ID: 21095116
[TBL] [Abstract][Full Text] [Related]
6. Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy--a representative sample survey in Germany.
Link H; Nietsch J; Kerkmann M; Ortner P;
Support Care Cancer; 2016 Jan; 24(1):367-376. PubMed ID: 26081593
[TBL] [Abstract][Full Text] [Related]
7. Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?
Skedgel C; Rayson D; Younis T
Support Care Cancer; 2016 Jan; 24(1):387-394. PubMed ID: 26081595
[TBL] [Abstract][Full Text] [Related]
8. Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer.
Griffiths RI; Barron RL; Gleeson ML; Danese MD; O'Hagan A; Chia VM; Legg JC; Lyman GH
Pharmacoeconomics; 2012 Feb; 30(2):103-18. PubMed ID: 21967155
[TBL] [Abstract][Full Text] [Related]
9. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.
Renner P; Milazzo S; Liu JP; Zwahlen M; Birkmann J; Horneber M
Cochrane Database Syst Rev; 2012 Oct; 10():CD007913. PubMed ID: 23076939
[TBL] [Abstract][Full Text] [Related]
10. G-CSF guideline adherence in Germany, an update with a retrospective and representative sample survey.
Link H; Kerkmann M; Holtmann L; Ortner P;
Support Care Cancer; 2019 Apr; 27(4):1459-1469. PubMed ID: 30374765
[TBL] [Abstract][Full Text] [Related]
11. Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia.
Aarts MJ; Peters FP; Mandigers CM; Dercksen MW; Stouthard JM; Nortier HJ; van Laarhoven HW; van Warmerdam LJ; van de Wouw AJ; Jacobs EM; Mattijssen V; van der Rijt CC; Smilde TJ; van der Velden AW; Temizkan M; Batman E; Muller EW; van Gastel SM; Borm GF; Tjan-Heijnen VC
J Clin Oncol; 2013 Dec; 31(34):4290-6. PubMed ID: 23630211
[TBL] [Abstract][Full Text] [Related]
12. Suboptimal duration of granulocyte colony-stimulating factor use and chemotherapy-induced neutropenia in women diagnosed with breast cancer.
Lin WT; Wen YW; Chien CR; Gau CS; Chiang SC; Hsiao FY
Clin Ther; 2014 Sep; 36(9):1287-94. PubMed ID: 25130388
[TBL] [Abstract][Full Text] [Related]
13. Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy--findings from clinical practice.
Krzemieniecki K; Sevelda P; Erdkamp F; Smakal M; Schwenkglenks M; Puertas J; Trojan A; Szabo Z; Bendall K; Maenpaa J
Support Care Cancer; 2014 Mar; 22(3):667-77. PubMed ID: 24154740
[TBL] [Abstract][Full Text] [Related]
14. Febrile neutropenia and role of prophylactic granulocyte colony-stimulating factor in docetaxel and cyclophosphamide chemotherapy for breast cancer.
Kimura Y; Sasada S; Emi A; Masumoto N; Kadoya T; Okada M
Support Care Cancer; 2021 Jul; 29(7):3507-3512. PubMed ID: 33146835
[TBL] [Abstract][Full Text] [Related]
15. Risks and consequences of travel burden on prophylactic granulocyte colony-stimulating factor administration and incidence of febrile neutropenia in an aged Medicare population.
Stephens JM; Bensink M; Bowers C; Hollenbeak CS
Curr Med Res Opin; 2019 Feb; 35(2):229-240. PubMed ID: 29661043
[TBL] [Abstract][Full Text] [Related]
16. Granulocyte colony-stimulating factor (G-CSF) patterns of use in cancer patients receiving myelosuppressive chemotherapy.
Choi MR; Solid CA; Chia VM; Blaes AH; Page JH; Barron R; Arneson TJ
Support Care Cancer; 2014 Jun; 22(6):1619-28. PubMed ID: 24492928
[TBL] [Abstract][Full Text] [Related]
17. Impact of granulocyte-colony stimulating factor on docetaxel-induced febrile neutropenia in patients with breast cancer.
Zekri J; Nawaz A; Rasool H; Ahmad I; Abdel Rahman H; Dada R; Abdelghany EM; Farag K; Ibrahim RB; Deibas MY; Kamel MK; Allithy A
J Oncol Pharm Pract; 2022 Dec; 28(8):1681-1686. PubMed ID: 34342555
[TBL] [Abstract][Full Text] [Related]
18. Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice.
Averin A; Silvia A; Lamerato L; Richert-Boe K; Kaur M; Sundaresan D; Shah N; Hatfield M; Lawrence T; Lyman GH; Weycker D
Support Care Cancer; 2021 Apr; 29(4):2179-2186. PubMed ID: 32880732
[TBL] [Abstract][Full Text] [Related]
19. Real-World Impact of Prophylactic Growth Factor Use on Timing of Febrile Neutropenia and Infection After High-Risk Chemotherapy.
Blayney DW; Kuderer NM; Cummings Joyner AK; Jarvis J; Nunag D; Wells J; Huang L; Mohanlal R; Lyman GH
J Natl Compr Canc Netw; 2023 Sep; 21(9):945-950.e16. PubMed ID: 37673111
[TBL] [Abstract][Full Text] [Related]
20. Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin's lymphoma patients receiving high (> 20%) FN-risk chemotherapy: results from a prospective observational study.
Salmon JP; Smakal M; Karanikiotis C; Wojtukiewicz MZ; Omnes Y; DeCosta L; Wetten S; O'Kelly J
Support Care Cancer; 2019 Apr; 27(4):1449-1457. PubMed ID: 30259136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
